Natco Pharma shares gained more than 12% intraday on Monday after the drugmaker informed the exchanges that the US Supreme Court Chief Justice has denied a request made by Teva to pass a stay order on the launch of Copaxone.
Teva Pharmaceuticals and Natco Pharma are locked in a patent fight for Copaxone, a drug used to treat multiple sclerosis.
The scrip was trading 7.30% higher at Rs 767.90 on the BSE at 12.30 pm IST.